Wedbush Securities Inc. Has $770,000 Stake in Alexion Pharmaceuticals, Inc. (ALXN)
Wedbush Securities Inc. grew its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 4.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,698 shares of the biopharmaceutical company’s stock after purchasing an additional 231 shares during the period. Wedbush Securities Inc.’s holdings in Alexion Pharmaceuticals were worth $770,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Parametrica Management Ltd purchased a new stake in Alexion Pharmaceuticals during the fourth quarter worth about $610,000. Prudential PLC purchased a new stake in Alexion Pharmaceuticals during the fourth quarter worth about $17,518,000. Ingalls & Snyder LLC increased its holdings in Alexion Pharmaceuticals by 18.9% during the first quarter. Ingalls & Snyder LLC now owns 26,693 shares of the biopharmaceutical company’s stock worth $3,608,000 after buying an additional 4,249 shares during the last quarter. Pinnacle Associates Ltd. increased its holdings in Alexion Pharmaceuticals by 14.9% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,600 shares of the biopharmaceutical company’s stock worth $1,129,000 after buying an additional 1,500 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its holdings in Alexion Pharmaceuticals by 134.3% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 218,688 shares of the biopharmaceutical company’s stock worth $21,291,000 after buying an additional 125,344 shares during the last quarter. Institutional investors own 95.01% of the company’s stock.
ALXN opened at $126.01 on Friday. The stock has a market capitalization of $28.16 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 0.96 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.88 and a quick ratio of 2.48. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86.
In other news, CAO Daniel Bazarko sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $126.00, for a total value of $252,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,020 shares in the company, valued at $632,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.08% of the stock is currently owned by company insiders.
A number of analysts recently issued reports on the stock. Raymond James initiated coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, April 10th. They set an “outperform” rating and a $161.00 price objective for the company. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $186.00 target price (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 27th. Cowen reiterated a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 13th. Finally, Guggenheim reiterated a “neutral” rating and issued a $135.00 target price on shares of Alexion Pharmaceuticals in a research note on Thursday, March 21st. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $162.06.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: Analyst Ratings Trading
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.